Galena Biopharma Acquires Mills Pharmaceuticals
January 13, 2014 at 07:10 AM EST
Galena Biopharma (Nasdaq: GALE ) today announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide. Galena expects to pursue the expedited 505(b)(2) regulatory pathway to seek approval of GALE-401 for the treatment of Essential Thrombocythemia (ET).
